1. Home
  2. |Insights
  3. |Healthy Data Management: Essential Strategies for Governing PHI, PII, and Highly Sensitive Data during an Acquisition or Divestiture

Healthy Data Management: Essential Strategies for Governing PHI, PII, and Highly Sensitive Data during an Acquisition or Divestiture

Webinar | 09.08.16, 9:00 AM EDT - 10:00 AM EDT

The merger and divestiture process for any type of company raises issues of data management and protection, particularly with the ease employees use technology to collect, store, and use data. Due to the nature of the confidential data that health care, life sciences, and pharmaceutical companies create and retain, these types of organizations face higher standards and specific issues related to the retention and protection of data when engaged in the merger or divestiture transaction process. Companies must balance the demand for access and sharing of data to meet business needs with legal and compliance obligations to protect highly sensitive data.


Join this webinar for a 60-minute panel discussion covering the information governance life cycle for health care, life sciences, and pharmaceutical companies, from identification of sensitive data to storing and protecting that data during mergers and divestitures. You will gain insight on how to effectively manage and store your data as well as tips for developing an information governance program designed specifically to handle the type of sensitive data your health-focused company maintains.


Elliot Golding is speaking at this webinar.


For more information, please visit these areas: Litigation and Trial, Privacy and Cybersecurity

Insights

Webinar | 10.16.25

The Artificial Intelligence Agenda from Capitol Hill to State Capitals: Where We Are and Where We Are (Probably) Going

The landscape of AI governance and regulation is shifting. Following the release of the White House’s “America’s AI Action Plan” in July 2025 and the President’s signing of related Executive Orders, the White House has emphasized (at least rhetorically) a preference for innovation, adoption, and deregulation. But that does not tell the entire story. The Administration remains committed to exercising a heavy hand in AI, including by banning the U.S. government’s procurement of so-called “woke AI,” intervening in the development of data centers and the export of the AI technology stack, imposing an export fee for certain semiconductors to China, and assuming a stake in a U.S. semiconductor company. State legislatures are also racing to implement their own regulations, particularly around AI’s use in critical areas, such as healthcare, labor and employment, and data privacy. The many sources of regulation raise the specter of a fragmented compliance environment for businesses. This webinar will delve into the Administration’s AI strategy, going beyond the headlines to analyze:...

View All Insights